Sanofi ADR (SNY)vsMolson Coors Beverage Company (TAP-A)
SNY
Sanofi ADR
$43.31
+0.30%
HEALTHCARE · Cap: $103.45B
TAP-A
Molson Coors Beverage Company
$42.98
-4.36%
CONSUMER DEFENSIVE · Cap: $8.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Sanofi ADR generates 323% more annual revenue ($47.35B vs $11.19B). SNY leads profitability with a 16.0% profit margin vs -18.9%. SNY appears more attractively valued with a PEG of 3.76. SNY earns a higher WallStSmart Score of 51/100 (C-).
SNY
Buy51
out of 100
Grade: C-
TAP-A
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+24.9%
Fair Value
$62.64
Current Price
$43.31
$19.33 discount
Intrinsic value data unavailable for TAP-A.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Strong operational efficiency at 20.0%
Generating 1.7B in free cash flow
Reasonable price relative to book value
Earnings expanding 35.6% YoY
Areas to Watch
ROE of 6.6% — below average capital efficiency
Expensive relative to growth rate
Earnings declined 11.7%
2.0% revenue growth
Weak financial health signals
Expensive relative to growth rate
ROE of -18.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.
Bull Case : TAP-A
The strongest argument for TAP-A centers on Price/Book, EPS Growth.
Bear Case : SNY
The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.
Bear Case : TAP-A
The primary concerns for TAP-A are Revenue Growth, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
SNY profiles as a mature stock while TAP-A is a turnaround play — different risk/reward profiles.
TAP-A carries more volatility with a beta of 0.44 — expect wider price swings.
SNY is growing revenue faster at 6.0% — sustainability is the question.
SNY generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
SNY scores higher overall (51/100 vs 50/100), backed by strong 16.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Molson Coors Beverage Company
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
The Molson Coors Beverage Company, commonly known as Molson Coors, is a multinational drink and brewing company headquartered in Chicago in the United States.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?